ClinicalTrials.gov record
Terminated Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

ClinicalTrials.gov ID: NCT00958269

Public ClinicalTrials.gov record NCT00958269. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment Including Subjects on Hemodialysis

Study identification

NCT ID
NCT00958269
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Phenomix
Industry
Enrollment
360 participants

Conditions and interventions

Interventions

  • dutogliptin Drug
  • placebo Drug
  • sitagliptin Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2009
Primary completion
Aug 31, 2011
Completion
Oct 31, 2011
Last update posted
Feb 2, 2010

2009 – 2011

United States locations

U.S. sites
23
U.S. states
13
U.S. cities
21
Facility City State ZIP Site status
Phenomix Investigational Site 115 Tempe Arizona
Phenomix Investigational Site 121 Long Beach California
Phenomix Investigational Site 110 Lynwood California
Phenomix Investigational Site 118 Lynwood California
Phenomix Investigational Site 119 Orange California
Phenomix Investigational Site 109 Palm Springs California
Phenomix Investigational Site 122 Whittier California
Phenomix Investigational Site 112 Lauderdale Lakes Florida
Phenomix Investigational Site 104 Ocala Florida
Phenomix Investigational Site 116 Pembroke Pines Florida
Phenomix Investigational Site 101 Augusta Georgia
Phenomix Investigational Site 117 Honolulu Hawaii
Phenomix Investigational Site 102 Baton Rouge Louisiana
Phenomix Investigational Site 100 Rockville Maryland
Phenomix Investigational Site 125 Rockville Maryland
Phenomix Investigational Site 114 Springfield Gardens New York
Phenomix Investigational Site 120 Winston-Salem North Carolina
Phenomix Investigational Site 107 Columbia South Carolina
Phenomix Investigational Site 111 Nashville Tennessee
Phenomix Investigational Site 103 Fort Worth Texas
Phenomix Investigational Site 106 Houston Texas
Phenomix Investigational Site 108 San Antonio Texas
Phenomix Investigational Site 113 Alexandria Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00958269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2010 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00958269 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →